Related Experiment Video
Updated: Jun 19, 2026
23:33
The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation
Published on: February 28, 2012
[Dabigatran (Pradaxa): efficacy and safety].
1Service d'Anesthésie Réanimation, Hôpital Cochin, 75014 Paris, France. nadia.rosencher@cch.aphp.fr
Annales Francaises D'Anesthesie Et De Reanimation
|October 31, 2009
Summary
New oral anticoagulants like dabigatran etexilate offer advantages over traditional low-molecular-weight heparins for preventing blood clots after surgery. Dabigatran etexilate provides a convenient, fixed-dose, once-daily oral option requiring no routine monitoring.
Area of Science:
- Pharmacology and Thrombosis Research
- Development of Novel Anticoagulant Therapies
- Clinical Trial Analysis of Hemostatic Agents
Context:
- Limitations of current low-molecular-weight heparins (LMWHs) include parenteral administration and frequent platelet monitoring.
- Need for orally available anticoagulants with predictable pharmacokinetics and minimal drug interactions.
- Advancements in direct thrombin inhibitors for thrombotic disorder prevention.
Purpose:
- To evaluate the efficacy and safety of dabigatran etexilate as an oral anticoagulant for VTE prevention.
- To compare dabigatran etexilate with subcutaneous enoxaparin in patients undergoing hip and knee arthroplasty.
- To assess the suitability of dabigatran etexilate for outpatient use and fixed-dose administration.
Summary:
- Dabigatran etexilate, an oral direct thrombin inhibitor, demonstrated non-inferiority to enoxaparin in major trials for VTE prevention post-arthroplasty.
- Clinical trials involving over 8,000 patients showed dabigatran etexilate's rapid onset, predictable action, and suitability for once-daily dosing.
- Approved in the EU and Canada, dabigatran etexilate offers a safe and effective oral alternative to LMWHs, simplifying patient care.
Impact:
- Provides a new oral anticoagulant option, improving patient convenience and adherence.
- Reduces the need for frequent monitoring and parenteral administration associated with LMWHs.
- Facilitates early discharge and outpatient management of patients at risk for venous thromboembolism.
Related Concept Videos
01:18Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
01:29Venous Thrombosis III: Interprofessional Care
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
01:29Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care
Diagnosing Pulmonary EmbolismDiagnosing pulmonary embolism (PE) involves clinical assessment and advanced imaging tests. The preferred diagnostic tool is the spiral (helical) CT scan or CT angiography (CTA), which uses intravenous contrast media to visualize the pulmonary vasculature and identify emboli.A ventilation-perfusion (V/Q) scan is an alternative for patients unable to receive contrast media. This scan includes both perfusion and ventilation scanning. Perfusion scanning involves...
01:20Venous Thrombosis II: Clinical Manifestations and Diagnostic Studies
The key difference between Superficial Vein Thrombosis (SVT) and Deep Vein Thrombosis (DVT) lies in their location and severity.Clinical ManifestationsSVT typically presents with localized pain, tenderness, and redness along the course of a superficial vein, often accompanied by a palpable, cord-like structure under the skin. This condition is usually less dangerous than DVT but can be uncomfortable and may lead to complications such as cellulitis or, rarely, a clot extension into the deep...